| __timestamp | Regeneron Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1271353000 | 47795223 |
| Thursday, January 1, 2015 | 1620577000 | 50426000 |
| Friday, January 1, 2016 | 2052295000 | 70853000 |
| Sunday, January 1, 2017 | 2075142000 | 78168000 |
| Monday, January 1, 2018 | 2186100000 | 123757000 |
| Tuesday, January 1, 2019 | 3036600000 | 140963000 |
| Wednesday, January 1, 2020 | 2735000000 | 131773000 |
| Friday, January 1, 2021 | 2908100000 | 210328000 |
| Saturday, January 1, 2022 | 3592500000 | 235780000 |
| Sunday, January 1, 2023 | 4439000000 | 244990000 |
| Monday, January 1, 2024 | 5132000000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Travere Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.
Regeneron has consistently increased its R&D budget, with a remarkable 250% growth from 2014 to 2023. This surge underscores Regeneron's dedication to pioneering new treatments and maintaining its leadership in the biotech sector. By 2023, Regeneron's R&D expenses reached an impressive $4.4 billion, reflecting its robust pipeline and strategic focus on innovation.
In contrast, Travere Therapeutics has shown a more modest increase in R&D spending, growing by approximately 400% over the same period. While its budget is smaller, peaking at $245 million in 2023, Travere's focused investments highlight its strategic efforts to carve out a niche in rare disease treatments.
Novartis AG or Regeneron Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Sanofi and Regeneron Pharmaceuticals, Inc. Allocate Funds
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alpine Immune Sciences, Inc.
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs Ionis Pharmaceuticals, Inc.
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Research and Development: Comparing Key Metrics for Regeneron Pharmaceuticals, Inc. and ACADIA Pharmaceuticals Inc.
R&D Spending Showdown: Genmab A/S vs Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Verona Pharma plc vs Travere Therapeutics, Inc.
Research and Development Investment: Viking Therapeutics, Inc. vs Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Travere Therapeutics, Inc. vs Xencor, Inc.